Literature DB >> 25305565

The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Robert T Chen1, Baevin Carbery2, Lisa Mac3, Kenneth I Berns4, Louisa Chapman3, Richard C Condit4, Jean-Louis Excler5, Marc Gurwith6, Michael Hendry3, Arifa S Khan7, Najwa Khuri-Bulos8, Bettina Klug9, James S Robertson10, Stephen J Seligman11, Rebecca Sheets12, Anna-Lise Williamson13.   

Abstract

Recombinant viral vectors provide an effective means for heterologous antigen expression in vivo and thus represent promising platforms for developing novel vaccines against human pathogens from Ebola to tuberculosis. An increasing number of candidate viral vector vaccines are entering human clinical trials. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to improve our ability to anticipate potential safety issues and meaningfully assess or interpret safety data, thereby facilitating greater public acceptance when licensed. Published by Elsevier Ltd.

Entities:  

Keywords:  Immunization; Safety; Vaccines; Viral Vector

Mesh：

Substances：

Year:  2014        PMID： 25305565      PMCID： PMC4568939          DOI： 10.1016/j.vaccine.2014.09.035

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  30 in total

1.  Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico.

Authors:  F Raúl Velázquez; Romulo E Colindres; Concepción Grajales; M Teresa Hernández; María Guadalupe Mercadillo; F Javier Torres; MariaYolanda Cervantes-Apolinar; Rodrigo DeAntonio-Suarez; Eduardo Ortega-Barria; Maxim Blum; Thomas Breuer; Thomas Verstraeten
Journal:  Pediatr Infect Dis J       Date:  2012-07       Impact factor: 2.129

2.  Replicating viral vectors as HIV vaccines: summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference.

Authors:  J L Excler; C L Parks; J Ackland; H Rees; I D Gust; W C Koff
Journal:  Biologicals       Date:  2010-07       Impact factor: 1.856

Review 3.  Viruses - from pathogens to vaccine carriers.

Authors:  Juliana C Small; Hildegund C J Ertl
Journal:  Curr Opin Virol       Date:  2011-10       Impact factor: 7.090

4.  Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009-2010.

Authors:  Sharon K Greene; Melisa Rett; Eric S Weintraub; Lingling Li; Ruihua Yin; Anthony A Amato; Doreen T Ho; Sarah I Sheikh; Bruce H Fireman; Matthew F Daley; Edward A Belongia; Steven J Jacobsen; Roger Baxter; Tracy A Lieu; Martin Kulldorff; Claudia Vellozzi; Grace M Lee
Journal:  Am J Epidemiol       Date:  2012-05-11       Impact factor: 4.897

5.  Integrating safety and efficacy evaluation throughout vaccine research and development.

Authors:  George Curlin; Sarah Landry; Jessica Bernstein; Richard L Gorman; Barbara Mulach; Charles J Hackett; Stephanie Foster; Sarah E Miers; Patricia Strickler-Dinglasan
Journal:  Pediatrics       Date:  2011-04-18       Impact factor: 7.124

6.  Editors' introduction: Vaccine safety throughout the product life cycle.

Authors:  Daniel A Salmon; Andrew Pavia; Bruce Gellin
Journal:  Pediatrics       Date:  2011-04-18       Impact factor: 7.124

7.  Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.

Authors:  Glenda E Gray; Mary Allen; Zoe Moodie; Gavin Churchyard; Linda-Gail Bekker; Maphoshane Nchabeleng; Koleka Mlisana; Barbara Metch; Guy de Bruyn; Mary H Latka; Surita Roux; Matsontso Mathebula; Nivashnee Naicker; Constance Ducar; Donald K Carter; Adrien Puren; Niles Eaton; M Julie McElrath; Michael Robertson; Lawrence Corey; James G Kublin
Journal:  Lancet Infect Dis       Date:  2011-05-11       Impact factor: 25.071

Review 8.  Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment.

Authors:  Thomas P Monath; Stephen J Seligman; James S Robertson; Bruno Guy; Edward B Hayes; Richard C Condit; Jean Louis Excler; Lisa Marie Mac; Baevin Carbery; Robert T Chen
Journal:  Vaccine       Date:  2014-10-27       Impact factor: 3.641

9.  Template protocol for clinical trials investigating vaccines--focus on safety elements.

Authors:  Jan Bonhoeffer; Egeruan B Imoukhuede; Grace Aldrovandi; Novilia S Bachtiar; Eng-Soon Chan; Soju Chang; Robert T Chen; Rohini Fernandopulle; Karen L Goldenthal; James D Heffelfinger; Shah Hossain; Indira Jevaji; Ali Khamesipour; Sonali Kochhar; Mamodikoe Makhene; Elissa Malkin; David Nalin; Rebecca Prevots; Ranjan Ramasamy; Sarah Sellers; Johan Vekemans; Kenneth B Walker; Pam Wilson; Virginia Wong; Khalequz Zaman; Ulrich Heininger
Journal:  Vaccine       Date:  2013-03-13       Impact factor: 3.641

Review 10.  Applications and challenges of multivalent recombinant vaccines.

Authors:  Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452
View more
  16 in total

Review 1.  Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.

Authors:  David K Clarke; R Michael Hendry; Vidisha Singh; John K Rose; Stephen J Seligman; Bettina Klug; Sonali Kochhar; Lisa Marie Mac; Baevin Carbery; Robert T Chen
Journal:  Vaccine       Date:  2016-07-06       Impact factor: 3.641

2.  A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).

Authors:  Brett Leav; Walter Straus; Phil White; Alison Leav; Tashawnee Gaines; Grace Maggiacomo; Denny Kim; Emily R Smith; Marc Gurwith; Robert T Chen
Journal:  Vaccine       Date:  2022-06-09       Impact factor: 4.169

3.  Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.

Authors:  Pedro M Folegatti; Daniel Jenkin; Susan Morris; Sarah Gilbert; Denny Kim; James S Robertson; Emily R Smith; Emalee Martin; Marc Gurwith; Robert T Chen
Journal:  Vaccine       Date:  2022-06-14       Impact factor: 4.169

4.  Mathematical models for devising the optimal Ebola virus disease eradication.

Authors:  Shuo Jiang; Kaiqin Wang; Chaoqun Li; Guangbin Hong; Xuan Zhang; Menglin Shan; Hongbin Li; Jin Wang
Journal:  J Transl Med       Date:  2017-06-01       Impact factor: 5.531

Review 5.  Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis.

Authors:  Bettina Klug; James S Robertson; Richard C Condit; Stephen J Seligman; Marian P Laderoute; Rebecca Sheets; Anna-Lise Williamson; Marc Gurwith; Sonali Kochhar; Louisa Chapman; Baevin Carbery; Lisa M Mac; Robert T Chen
Journal:  Vaccine       Date:  2016-06-15       Impact factor: 3.641

Review 6.  Enhancing vaccine safety capacity globally: A lifecycle perspective.

Authors:  Robert T Chen; Tom T Shimabukuro; David B Martin; Patrick L F Zuber; Daniel M Weibel; Miriam Sturkenboom
Journal:  Vaccine       Date:  2015-10-01       Impact factor: 3.641

Review 7.  The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines.

Authors:  Denny Kim; James S Robertson; Jean-Louis Excler; Richard C Condit; Patricia E Fast; Marc Gurwith; George Pavlakis; Thomas P Monath; Jonathan Smith; David Wood; Emily R Smith; Robert T Chen; Sonali Kochhar
Journal:  Vaccine       Date:  2020-06-19       Impact factor: 3.641

8.  Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines.

Authors:  Sonali Kochhar; Jean-Louis Excler; Karin Bok; Marc Gurwith; Michael M McNeil; Stephen J Seligman; Najwa Khuri-Bulos; Bettina Klug; Marian Laderoute; James S Robertson; Vidisha Singh; Robert T Chen
Journal:  Vaccine       Date:  2018-11-26       Impact factor: 3.641

Review 9.  Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains.

Authors:  Richard C Condit; Anna-Lise Williamson; Rebecca Sheets; Stephen J Seligman; Thomas P Monath; Jean-Louis Excler; Marc Gurwith; Karin Bok; James S Robertson; Denny Kim; R Michael Hendry; Vidisha Singh; Lisa M Mac; Robert T Chen
Journal:  Vaccine       Date:  2016-06-23       Impact factor: 3.641

Review 10.  The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.

Authors:  Sonali Kochhar; Denny Kim; Jean-Louis Excler; Richard C Condit; James S Robertson; Stephen Drew; Mike Whelan; David Wood; Patricia E Fast; Marc Gurwith; Bettina Klug; Najwa Khuri-Bulos; Emily R Smith; Robert T Chen
Journal:  Vaccine       Date:  2020-07-09       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.